FURADANTIN (nitrofurantoin) by Aurobindo Pharma is clinical pharmacology each nitrofurantoin capsule (monohydrate/macrocrystals) contains two forms of nitrofurantoin. First approved in 1953.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
FURADANTIN (nitrofurantoin) is an oral small-molecule antibiotic used primarily for uncomplicated urinary tract infections (UTIs), particularly acute cystitis. It works by inhibiting bacterial enzymes and damaging bacterial DNA, with a dual-release formulation (75% monohydrate + 25% macrocrystalline) designed for prolonged urinary activity and improved tolerability. The monohydrate/macrocrystalline combination achieves similar urinary excretion profiles to standard macrocrystalline formulations while minimizing gastrointestinal side effects.
With LOE approaching and moderate competitive pressure (30/100), expect defensive brand positioning, cost optimization, and reduced commercial headcount as the product transitions toward generic-dominated market dynamics.
CLINICAL PHARMACOLOGY Each nitrofurantoin capsule (monohydrate/macrocrystals) contains two forms of nitrofurantoin. Twenty-five percent is macrocrystalline nitrofurantoin, which has slower dissolution and absorption than nitrofurantoin monohydrate. The remaining 75% is nitrofurantoin monohydrate…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
Worked on FURADANTIN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on FURADANTIN offers limited growth upside and declining team size as the product approaches loss of exclusivity; career development is constrained by the mature lifecycle and commodity competitive dynamics. Professionals on this product should expect transition planning, focus on cost efficiency, and lateral moves to growth-stage assets within the sponsor's portfolio.